PHIO Pharmaceuticals Corp. (PHIO) - Form 8-K Summary (Nov 3, 2025)

PHIO announced positive early clinical results from its ongoing Phase 1b dose escalation trial (NCT 06014086) for its INTASYL PH-762 treatment in cutaneous squamous cell carcinoma.

• Key Efficacy Data (Day 36):
  • One patient achieved 100% tumor clearance (Complete Response).
  • Second patient achieved >90% tumor reduction (Near Complete Response).
  • Third patient achieved >50% tumor reduction (Partial Response).
• Safety Monitoring: The Safety Monitoring Committee issued a **favorabl